JP2011236167A - Eye-drops and method for producing the same - Google Patents

Eye-drops and method for producing the same Download PDF

Info

Publication number
JP2011236167A
JP2011236167A JP2010110010A JP2010110010A JP2011236167A JP 2011236167 A JP2011236167 A JP 2011236167A JP 2010110010 A JP2010110010 A JP 2010110010A JP 2010110010 A JP2010110010 A JP 2010110010A JP 2011236167 A JP2011236167 A JP 2011236167A
Authority
JP
Japan
Prior art keywords
mineral water
eye
mineral
dilution
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010110010A
Other languages
Japanese (ja)
Other versions
JP4644305B1 (en
Inventor
Kimio Kawamura
喜美雄 川村
Daisuke Kojima
大輔 小島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2010110010A priority Critical patent/JP4644305B1/en
Application granted granted Critical
Publication of JP4644305B1 publication Critical patent/JP4644305B1/en
Publication of JP2011236167A publication Critical patent/JP2011236167A/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

PROBLEM TO BE SOLVED: To provide eye-drops and a method for producing the eye-drops composed of minerals as principal components and exhibiting excellent efficacy to relieving symptoms such as eyestrain and dry eyes by paying attention to effect of the minerals.SOLUTION: The method for producing eye-drops includes: a process for preparing mineral water; a process for diluting the mineral water with demineralized water; a process for precipitating impurities in the mineral water during the dilution or after the dilution, preferably by leaving the dilution at rest after heating it to 70°C or higher; and a process for collecting the supernatant obtained by precipitating the impurities. The process for preparing the mineral water includes a process for dissolving granite porphyry or other ores with acetic acid.

Description

本発明は点眼薬及びその製造方法に関するものであり、より詳細には、長時間に亘るパソコン等の使用による眼精疲労やドライアイ、飛蚊症、あるいは、老化に伴う視力低下等に顕著な効能が認められる点眼薬及びその製造方法に関するものである。   The present invention relates to eye drops and a method for producing the same. More specifically, the present invention is prominent in eyestrain caused by long-term use of a personal computer or the like, dry eye, flying mosquito disease, or a decrease in visual acuity associated with aging. The present invention relates to an ophthalmic solution whose efficacy is recognized and a method for producing the same.

近時、パソコンを使用しての業務が増加し、老若男女を問わず、長時間に亘ってパソコン操作をする者が増えてきている。そして、長時間に亘ってパソコン操作をする結果、肩凝りや眼精疲労を訴える者が多数に上る。また、パソコンの使用だけでなく、コンタクトレンズの使用やエアコンの普及に伴い、ドライアイ(乾き目)症状の者が増加している。一般に、このような眼精疲労やドライアイの症状を和らげるために、ビタミンやヒアルロン酸等を含有した点眼薬が用いられている。   In recent years, the use of personal computers has increased, and there are an increasing number of people who operate personal computers for a long time regardless of gender. As a result of operating the personal computer for a long time, many people complain of stiff shoulders and eye strain. In addition to the use of personal computers, the use of contact lenses and the spread of air conditioners are increasing the number of people with dry eye symptoms. In general, eye drops containing vitamins, hyaluronic acid and the like are used to relieve such symptoms of eye strain and dry eye.

しかし、これらビタミンやヒアルロン酸等は、本来、口から取り入れることにより体内に吸収され、その効果を発揮するものと考えられるので、これらの成分を点眼薬に含有させても、眼精疲労やドライアイの症状を和らげる顕著な効果を期待することはできない。また、ミネラルを含有する点眼薬も存するが、その場合のミネラル含有量は少量であるところから明らかなように、それらは、ミネラルによる効果に着目してその効能を期待するものではない。   However, these vitamins, hyaluronic acid, and the like are originally absorbed into the body by taking them through the mouth and are considered to exert their effects. It is not possible to expect a noticeable effect to relieve eye symptoms. In addition, there are eye drops containing minerals, but as is clear from the fact that the mineral content in that case is small, they are not expected to be effective by paying attention to the effects of minerals.

特表2009−515821号公報Special table 2009-515821 特表2008−500282号公報Special table 2008-500282 特表2002−522382号公報Japanese translation of PCT publication No. 2002-522382

上述したように、眼精疲労やドライアイの症状を和らげる効果のある点眼薬で、殊に、これらの症状に対するミネラルによる効果に着目した点眼薬は提唱されていなかった。そこで本発明は、ミネラルの効果に着目し、これを主成分としていて、眼精疲労やドライアイの症状を和らげるのに優れた効果を発揮する点眼薬及びその製造方法を提供することを課題とする。   As described above, no ophthalmic solution has been proposed that is effective in relieving the symptoms of eye strain and dry eye, and particularly focusing on the effects of minerals on these symptoms. Then, this invention pays attention to the effect of a mineral, and has as a subject to provide the eyedrop which has this as a main component, and exhibits the effect excellent in relieving the symptoms of eye strain and dry eye, and its manufacturing method. To do.

人間の細胞は基本的にはミネラルであるので、細胞が正常に機能するためには、ミネラル成分が不可欠であることは言うまでもない。そこで、本発明者らは、ミネラルを主成分とした点眼薬を用いれば、そのミネラル成分が眼から吸収されて、種々の眼病の症状緩和に有効に作用するであろうとの知見を得て、本発明をなしたものである。   Since human cells are basically minerals, it goes without saying that mineral components are essential for the normal functioning of cells. Therefore, the present inventors have obtained the knowledge that if an eye drop containing a mineral as a main component is used, the mineral component will be absorbed from the eye and will effectively act to alleviate the symptoms of various eye diseases. The present invention has been made.

即ち、上記課題を解決するための請求項1に記載の発明は、ミネラル水を純水で希釈して成るミネラルを主成分とする点眼薬である。好ましい実施形態においては、前記ミネラル水は、花崗斑岩その他の鉱石を酢酸で溶解したものとされ、生理的食塩水を更に含有するものとされ、その場合のミネラル水と純水と生理的食塩水の混合比率は、好ましくは、約0.8〜1.3:8.2〜7.7:1、より好ましくは、約1:8:1にされる。   That is, the invention according to claim 1 for solving the above-described problem is an eye drop mainly composed of a mineral obtained by diluting mineral water with pure water. In a preferred embodiment, the mineral water is a granite porphyry or other ore dissolved with acetic acid, and further contains physiological saline. In that case, the mineral water, pure water, and physiological water The mixing ratio of the saline is preferably about 0.8 to 1.3: 8.2 to 7.7: 1, more preferably about 1: 8: 1.

また、上記課題を解決するための請求項4に記載の発明は、ミネラル水を用意する工程と、前記ミネラル水を純水で希釈する工程と、前記希釈時又は希釈後に所定温度以上に加温した後静置して、前記ミネラル水中の不純物を沈殿させる工程と、前記不純物を沈殿させることにより得られる上澄み液を回収する工程とから成ることを特徴とする点眼薬の製造方法である。   In addition, the invention according to claim 4 for solving the above-described problems includes a step of preparing mineral water, a step of diluting the mineral water with pure water, and heating to a predetermined temperature or higher during or after the dilution. Then, it is allowed to stand and precipitate the impurities in the mineral water, and a method for producing an eye drop comprising the step of collecting the supernatant obtained by precipitating the impurities.

好ましい実施形態においては、前記ミネラル水を用意する工程は、花崗斑岩その他の鉱石を酢酸で溶解する工程とされ、前記所定温度は70℃とされる。また、生理的食塩水を添加する工程を更に含み、その場合、ミネラル水と純水と生理的食塩水の混合比率は、好ましくは、約0.8〜1.3:8.2〜7.7:1、より好ましくは、約1:8:1となるようにされる。前記生理的食塩水を添加する工程は、前記上澄み液の回収工程後に実施される。   In a preferred embodiment, the step of preparing the mineral water is a step of dissolving granite porphyry or other ore with acetic acid, and the predetermined temperature is 70 ° C. The method further includes the step of adding physiological saline, in which case the mixing ratio of mineral water, pure water, and physiological saline is preferably about 0.8 to 1.3: 8.2 to 7. 7: 1, more preferably about 1: 8: 1. The step of adding physiological saline is performed after the step of collecting the supernatant.

本発明は上述したとおりであって、本発明に係る点眼薬は、花崗斑岩その他の鉱石を酢酸で溶解したミネラル水を純水で希釈し、その希釈時又は希釈後に所定温度以上に加温した後静置してミネラル水中の不純物を沈殿させることにより得られる上澄み液から成るミネラルを主成分とするものであって、希釈時又は希釈後に、好ましくは70℃以上に加温することにより、不純物が大きな結晶として沈殿分離されるために、有効なミネラル成分のみを含有するクリーンなものとなり、種々の眼病の症状を十分に緩和させる効能のある点眼薬が得られる効果がある。   The present invention is as described above, and the eye drop according to the present invention is obtained by diluting mineral water obtained by dissolving granite porphyry or other ore with acetic acid with pure water, and adding it to a predetermined temperature or higher during or after the dilution. It is composed mainly of a mineral composed of a supernatant obtained by precipitating after warming and precipitating impurities in mineral water, and is preferably heated to 70 ° C. or more at the time of dilution or after dilution. Since the impurities are precipitated and separated as large crystals, it becomes a clean substance containing only effective mineral components, and there is an effect that eye drops having the effect of sufficiently relieving various eye disease symptoms can be obtained.

以下に、本発明を実施するための形態について説明する。本発明に係る点眼薬は、ミネラル水を純水で希釈して成るミネラルを主成分とするものであり、好ましくは、更に生理的食塩水を含有するものである。そして、その点眼薬を製造するための本発明に係る方法は、ミネラル水を用意する工程、前記ミネラル水を純水で希釈する工程、前記希釈時又は希釈後に加温した後静置して、前記ミネラル水中の不純物を沈殿させる工程、及び、前記不純物を沈殿させることにより得られる上澄み液を採取する工程とから成ることを特徴とする。以下に、各工程についてより詳細に説明する。   Below, the form for implementing this invention is demonstrated. The eye drop according to the present invention is mainly composed of a mineral obtained by diluting mineral water with pure water, and preferably further contains physiological saline. And, the method according to the present invention for producing the eye drops includes a step of preparing mineral water, a step of diluting the mineral water with pure water, and heating after the dilution or after dilution. The method comprises a step of precipitating impurities in the mineral water, and a step of collecting a supernatant obtained by precipitating the impurities. Below, each process is demonstrated in detail.

本発明において用いるミネラル水としては、例えば、花崗斑岩その他の鉱石を原料にし、酢酸により抽出して製造したものを用いることが推奨される。本発明に係る点眼薬は、このミネラル水を純水で希釈して得られるものであり、その状態で用いてもそれなりの効果は期待できる。   As the mineral water used in the present invention, for example, it is recommended to use a granulated porphyry or other ore extracted from acetic acid. The eye drops according to the present invention are obtained by diluting this mineral water with pure water, and even if used in that state, a certain effect can be expected.

しかし、単にミネラル水を純水で希釈しただけのものは、希釈後数時間の内に液全体が濁り始め、数日後には目視可能な濁りとなり、やがて、浮遊物が目視可能な状態にまでなる。これは、原料の花崗斑岩等の鉱石を酢酸で溶解して成分抽出するために、有効なミネラル成分の他に、不要な成分が含有されることに起因するものと推測される。   However, when the mineral water is simply diluted with pure water, the entire liquid begins to become cloudy within a few hours after dilution, and becomes visibly cloudy after a few days. Become. This is presumably due to the inclusion of unnecessary components in addition to effective mineral components in order to extract ores such as granite porphyry from raw materials by dissolving them with acetic acid.

このような濁りのある点眼薬は、たとえ効能があるとしても、目脂の原因になったり、時に痛みを伴ったりすることがあるために、使用をためらう者が少なくない。そこで、本発明らはこの濁りをなくすべく研究を進めた結果、その濁りの問題を解消するには、その希釈時又は希釈後に所定温度以上に加温した後静置すればよいことを突き止めた。その加温温度は、70℃以上とすることが好ましい。このように、希釈時又は希釈後に加温すると、ミネラル水中の不純物が短時間の内に結晶化し、その後静置することにより、固体となって容器の底部に沈殿する。このようにして不純物が分離される結果、上澄み液は非常にクリアなものとなるので、この上澄み液を回収することとする。   Even if such an ophthalmic solution with turbidity is effective, it may cause eyelids and sometimes be accompanied by pain. Therefore, as a result of researches to eliminate this turbidity, the present inventors have found that in order to solve the problem of turbidity, it should be allowed to stand after being heated to a predetermined temperature or higher at the time of dilution or after dilution. . The heating temperature is preferably 70 ° C. or higher. Thus, when heated at the time of dilution or after dilution, impurities in the mineral water crystallize within a short time, and then settled to become a solid and precipitate at the bottom of the container. As a result of the impurities being separated in this way, the supernatant liquid becomes very clear, so that the supernatant liquid is recovered.

上記のように希釈液を、好ましくは70℃以上に加温するのは、不純物を大きな結晶として比較的短時間の内に沈殿させるためであり、例えば、20〜30℃の低温に加熱した場合は、不純物がミクロン単位の浮遊物となって液中に残存することになる。そして、この浮遊物を透過膜を用いて除去しようとすると、有効なミネラル成分まで除去されてしまうおそれがある。   The reason why the dilution liquid is heated to 70 ° C. or higher as described above is to precipitate impurities as a large crystal within a relatively short time, for example, when heated to a low temperature of 20 to 30 ° C. Will remain in the liquid as impurities in the micron unit. And if this floating substance is removed using a permeable membrane, there is a possibility that even an effective mineral component may be removed.

本発明者らの試験したところによると、濁りの発生は希釈直後より始まり、70℃以上に加熱した約48時間後に不純物同士の結晶化が顕著となり、約10日経過後に上澄み液がほぼ透明になるので、その後上澄み液を回収するようにする。   According to the tests by the present inventors, the occurrence of turbidity starts immediately after dilution, and crystallization of impurities becomes remarkable after about 48 hours heated to 70 ° C. or higher, and the supernatant liquid becomes almost transparent after about 10 days. Therefore, the supernatant is collected after that.

好ましくは、この上澄み液に、生理的食塩水を添加する。これは、生理的食塩水が、眼に対する有効成分の浸透を促進すると考えられるからである。この場合のミネラル水と純水と生理的食塩水の混合比率は、好ましくは、約1:8:1とされるが、ミネラル水をより高濃度(例えば、ミネラル水:純水=1.3:7.7)にし、あるいは、より低濃度(例えば、ミネラル水:純水=0.8:8.2)にすることもできる。   Preferably, physiological saline is added to the supernatant. This is because physiological saline is thought to promote penetration of the active ingredient into the eye. In this case, the mixing ratio of mineral water, pure water, and physiological saline is preferably about 1: 8: 1, but the mineral water has a higher concentration (for example, mineral water: pure water = 1.3). : 7.7), or a lower concentration (for example, mineral water: pure water = 0.8: 8.2).

以下に、上記のように生理的食塩水を添加した後の、ミネラルの成分表(100ml中)の一例を示す。
Mg 0.029mg
P 0.00013mg
Ca 0.00228mg
Se 0.000001mg
Cu 0.00001mg
Mn 0.00013mg
Na 0.0001mg
Fe 0.00069mg
Mn 0.00013mg
V 微量
Mo 微量
他の有用ミネラル 微量
Nacl 0.9g
The following is an example of a mineral composition table (in 100 ml) after adding physiological saline as described above.
Mg 0.029mg
P 0.00013mg
Ca 0.00228mg
Se 0.000001mg
Cu 0.00001mg
Mn 0.00013mg
Na 0.0001mg
Fe 0.00069mg
Mn 0.00013mg
V Trace Mo Trace Other useful mineral Trace Nacl 0.9g

本点眼薬は、既に50人以上のモニターによる試用を経て、その有効性が確認されている。以下に参考のために、モニターから寄せられた回答例を示す。
・世田谷区奥沢20代男性(商標デザイナー)
今まで様々な目薬を使用して来ましたが、これほど効果を実感したものはありません。
ドライアイですが一日5、6回の使用で問題なく業務が可能となっています。
・目黒区八雲20代男性(自営(パソコン使用))
仕事上ドライアイと飛蚊症がありましたが毎日の点眼で両方の症状は消失して快適な業
務が可能となっております。
・目黒区八雲40代女性(サラリーマン(パソコン使用))
使用開始から効果は表れ、眼精疲労から肩こりもひどく首の後ろも常に硬直しておりま
したが、点眼することで症状は軽減すると共に首の硬直もかなり改善しています。
・世田谷区奥沢50代女性(飲食業)
老眼は視力が低下するのは仕方ないと思っていましたが点眼して視力が回復して目が良
く見えるようになった。近所の年配者の女性にも試して貰ったら、同様の効果だと言っ
ておりました。
・横浜市60代(無職)
目薬をいつも手離せなかったのが、これを使用することでドライアイ等の症状がかなり
軽減した。
・世田谷区奥沢50代(医師)
使用直後に効果が分かった。ドライアイだが症状は明らかに軽減している。医師仲間に
も試して貰い好評です。
・世田谷区池上30代(自営酒類販売)
パソコン業務で目の疲労が激しかったのですが、とても調子が良くなりました。
・川崎市60代女性(主婦)
昨年までは春の花粉の時期は目に違和感があり、市販の目薬を使用していたが全く改善
はなく、今年は花粉症の目に対する影響だけはなく快適に過ごしている。目に多数回の
点眼で問題なし。
・横浜市40代女性(パート主婦)
パソコン業務で目の疲労は大変であったが、この点眼液の使用で仕事に対するマイナス
点はなし。ただ点眼後は視力が相当回復はするもののドライアイ状況は変化なし。
・大田区上池台50代女性(大使館勤務)
点眼をするようになってからはパソコンの仕事でもドライアイの症状はかなり改善し、
以前と比べても大変に楽な状況が続いている。これがなくては仕事が辛い。
・名古屋市豊明市60代男性(工員)
使用してすぐに効果が実感でき、現在では手離せません。
・府中市40代女性(外車販売業務)
今まではパソコン使用で夕方には目が疲れて視力が落ちているのが分かったがこの点眼
液で即効で回復するのが実感できる。
・横浜市30代(自動車販売営業)
仕事の中にはパソコンを使用する時間が多い時もあり、目の疲労には困っていたがこれ
を使用すると視力の回復を非常に実感できる。
The effectiveness of this eye drop has been confirmed through trials with more than 50 monitors. The following are examples of responses received from monitors for reference.
・ Setagaya-ku Okuzawa 20s male (trademark designer)
I have been using various eye drops so far, but nothing has been so effective.
Although it is dry eye, it is possible to work without problems by using it 5 or 6 times a day.
・ Meguro-ku Yakumo 20s male (self-employed (using computer))
Although I had dry eyes and flying mosquitoes on my job, daily symptoms gave me both symptoms and comfortable work.
・ Female in Meguro Yakumo 40s (company employee (using a computer))
The effect appeared from the start of use, and stiff shoulders due to eye strain, and the back of the neck was always stiff, but by instilling the symptoms alleviated and the stiffness of the neck improved considerably.
・ Female in Setagaya-ku Okuzawa 50s (restaurant)
The presbyopia thought that his visual acuity was unavoidable, but when he applied it, his visual acuity recovered and his eyes looked good. When I asked a senior elderly woman in the neighborhood, he said it would have the same effect.
・ Yokohama City 60s (unemployed)
Although I couldn't take my eye drops all the time, the use of this medicine significantly reduced the symptoms such as dry eye.
・ Setagaya-ku Okusawa 50s (doctor)
The effect was found immediately after use. Although it is dry eye, the symptoms are clearly alleviated. It has been well received by doctors.
・ Ikegami 30s (Setagaya-ku)
I had a lot of eye strain in my computer work, but I feel better.
・ Kawasaki City 60s Female (Housewife)
Until last year, the pollen period in spring was uncomfortable for the eyes, and I used a commercially available eye drop, but there was no improvement at all. No problem with instilling many times in the eyes.
・ Yokohama City 40s female (part-time housewife)
Although eye fatigue was serious in the personal computer business, there was no negative point for work by using this ophthalmic solution. However, although the eyesight recovered considerably after instillation, the dry eye situation remained unchanged.
・ Female, 50s, Kamiikedai, Ota-ku (working at the Embassy)
Since I started taking instillation, my dry eye symptoms have improved considerably even at work on my computer.
The situation continues to be much easier than before. Without this, work is difficult.
・ Toyoaki City, Nagoya City 60s male (engineer)
Immediately after use, you can feel the effect, and now it can not be released.
・ Fuchu City 40s female (foreign car sales)
Until now, I found that my eyes were tired and my vision decreased in the evening using a personal computer.
・ Yokohama City 30s (Automobile Sales)
There are times when I use a computer a lot during my work, and I was troubled with eye fatigue, but using this I can realize the recovery of my vision.

この発明をある程度詳細にその最も好ましい実施形態について説明してきたが、この発明の精神と範囲に反することなしに広範に異なる実施形態を構成することができることは明白なので、この発明は添付請求の範囲において限定した以外はその特定の実施形態に制約されるものではない。   Although the present invention has been described in some detail with respect to its most preferred embodiments, it will be apparent that a wide variety of different embodiments can be constructed without departing from the spirit and scope of the invention, the invention being defined by the appended claims. It is not restricted to the specific embodiment other than limiting in.

以下に、上記のように生理的食塩水を添加した後の、ミネラルの成分表(100ml中)の一例を示す。
Mg 0.029mg
P 0.00013mg
Ca 0.00228mg
Se 0.000001mg
Cu 0.00001mg
Mn 0.00013mg
Na 0.0001mg
Fe 0.00069mg
Mn 0.00013mg
V 微量
Mo 微量
他の有用ミネラル 微量
Nacl 0.09g
The following is an example of a mineral composition table (in 100 ml) after adding physiological saline as described above.
Mg 0.029mg
P 0.00013mg
Ca 0.00228mg
Se 0.000001mg
Cu 0.00001mg
Mn 0.00013mg
Na 0.0001mg
Fe 0.00069mg
Mn 0.00013mg
V Trace Mo Trace Other useful mineral Trace Nacl 0.09g

上記課題を解決するための請求項1に記載の発明は、花崗斑岩を酢酸で溶解して得たミネラル水を純水で希釈し、適宜生理的食塩水を含有させて成る点眼薬である。ミネラル水と純水と生理的食塩水の混合比率は、0.8〜1.3:8.2〜7.7:1とされ、好ましくは、1:8:1にされる。 The invention according to claim 1 for solving the above-mentioned problems is an eye drop obtained by diluting mineral water obtained by dissolving granite porphyry with acetic acid with pure water and appropriately containing physiological saline. is there. The mixing ratio of mineral water, pure water, and physiological saline is 0.8 to 1.3: 8.2 to 7.7: 1, and preferably 1: 8: 1.

また、上記課題を解決するための請求項4に記載の発明は、花崗斑岩を酢酸で溶解してミネラル水を得る工程と、前記ミネラル水を純水で希釈する工程と、前記希釈時又は希釈後に所定温度以上に加温した後静置して、前記希釈したミネラル水中の不純物を沈殿させる工程と、前記不純物を沈殿させることにより得られる上澄み液を回収する工程とから成ることを特徴とする点眼薬の製造方法である。 Further, the invention according to claim 4 for solving the above-mentioned problems is a step of dissolving mineral porphyry with acetic acid to obtain mineral water, a step of diluting the mineral water with pure water, and the time of the dilution. Alternatively, the method comprises a step of allowing the impurities in the diluted mineral water to settle after warming to a predetermined temperature or higher after dilution, and a step of recovering a supernatant obtained by precipitating the impurities. And a method for producing eye drops.

好ましい実施形態においては、前記所定温度は70℃とされる。また、生理的食塩水を添加する工程を更に含み、その場合、ミネラル水と純水と生理的食塩水の混合比率は、0.8〜1.3:8.2〜7.7:1とされ、好ましくは、1:8:1となるようにされる。前記生理的食塩水を添加する工程は、前記上澄み液の回収工程後に実施される。
In a preferred embodiment, the predetermined temperature is 70 ° C. The method further includes a step of adding physiological saline, in which case the mixing ratio of mineral water, pure water and physiological saline is 0.8 to 1.3: 8.2 to 7.7: 1. Preferably, the ratio is 1: 8: 1. The step of adding physiological saline is performed after the step of collecting the supernatant.

Claims (10)

ミネラル水を純水で希釈して成るミネラルを主成分とする点眼薬。   Eye drops mainly composed of minerals made by diluting mineral water with pure water. 前記ミネラル水は、花崗斑岩その他の鉱石を酢酸で溶解したものである、請求項1に記載の点眼薬。   The eye drop according to claim 1, wherein the mineral water is obtained by dissolving granite porphyry and other ores with acetic acid. 更に生理的食塩水を含有した、請求項1又は2に記載の点眼薬。   The eye drop according to claim 1 or 2, further comprising physiological saline. 前記ミネラル水と前記純水と前記生理的食塩水の混合比率が、約0.8〜1.3:8.2〜7.7:1、好ましくは、約1:8:1である、請求項3に記載の点眼薬。   The mixing ratio of the mineral water, the pure water and the physiological saline is about 0.8-1.3: 8.2-7.7: 1, preferably about 1: 8: 1. Item 4. Eyedrops. ミネラル水を用意する工程と、
前記ミネラル水を純水で希釈する工程と、
前記希釈時又は希釈後に所定温度以上に加温した後静置して、前記ミネラル水中の不純物を沈殿させる工程と、
前記不純物を沈殿させることにより得られる上澄み液を回収する工程
とから成ることを特徴とする点眼薬の製造方法。
A process of preparing mineral water;
Diluting the mineral water with pure water;
A step of precipitating impurities in the mineral water by standing after being heated to a predetermined temperature or higher at the time of dilution or after dilution;
And a step of recovering a supernatant obtained by precipitating the impurities.
前記ミネラル水を用意する工程は、花崗斑岩その他の鉱石を酢酸で溶解する工程から成る、請求項5に記載の点眼薬の製造方法。   The method for producing eye drops according to claim 5, wherein the step of preparing the mineral water comprises a step of dissolving granite porphyry or other ores with acetic acid. 前記所定温度は70℃である、請求項5に記載の点眼薬の製造方法。   The method for producing eye drops according to claim 5, wherein the predetermined temperature is 70 ° C. 更に生理的食塩水を添加する工程を含む、請求項5乃至7のいずれかに記載の点眼薬の製造方法。 The method for producing eye drops according to any one of claims 5 to 7, further comprising a step of adding physiological saline. 前記生理的食塩水を添加する工程は、前記上澄み液の回収工程後に実施する、請求項8に記載の点眼薬の製造方法。   The method for producing eye drops according to claim 8, wherein the step of adding physiological saline is performed after the step of collecting the supernatant. 前記ミネラル水と前記純水と前記生理的食塩水の混合比率を、約0.8〜1.3:8.2〜7.7:1、好ましくは、約1:8:1とする、請求項8又は9に記載の点眼薬の製造方法。   The mixing ratio of the mineral water, the pure water, and the physiological saline is about 0.8-1.3: 8.2-7.7: 1, preferably about 1: 8: 1. Item 10. A method for producing an eye drop according to Item 8 or 9.
JP2010110010A 2010-05-12 2010-05-12 Eye drops and production method thereof Expired - Fee Related JP4644305B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010110010A JP4644305B1 (en) 2010-05-12 2010-05-12 Eye drops and production method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010110010A JP4644305B1 (en) 2010-05-12 2010-05-12 Eye drops and production method thereof

Publications (2)

Publication Number Publication Date
JP4644305B1 JP4644305B1 (en) 2011-03-02
JP2011236167A true JP2011236167A (en) 2011-11-24

Family

ID=43836039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010110010A Expired - Fee Related JP4644305B1 (en) 2010-05-12 2010-05-12 Eye drops and production method thereof

Country Status (1)

Country Link
JP (1) JP4644305B1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226225A (en) * 1985-05-29 1987-02-04 アイ・リサ−チ・インステイテユ−ト・オブ・ザ・レテイナ・フアウンデイシヨン Nontoxic ophthalmic medicine
JPH08169835A (en) * 1994-07-25 1996-07-02 Lab Medidom Sa Pharmaceutical preparation for eye for using it as artificial tear
JP2000159659A (en) * 1998-11-30 2000-06-13 Kazuo Tsubota Artificial lachrymal fluid for ophthalmology
JP2003093467A (en) * 2001-09-27 2003-04-02 Randakku:Kk Jet washer
JP2009072723A (en) * 2007-09-21 2009-04-09 Tamotsu Hiroshima Mineral water making method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226225A (en) * 1985-05-29 1987-02-04 アイ・リサ−チ・インステイテユ−ト・オブ・ザ・レテイナ・フアウンデイシヨン Nontoxic ophthalmic medicine
JPH08169835A (en) * 1994-07-25 1996-07-02 Lab Medidom Sa Pharmaceutical preparation for eye for using it as artificial tear
JP2000159659A (en) * 1998-11-30 2000-06-13 Kazuo Tsubota Artificial lachrymal fluid for ophthalmology
JP2003093467A (en) * 2001-09-27 2003-04-02 Randakku:Kk Jet washer
JP2009072723A (en) * 2007-09-21 2009-04-09 Tamotsu Hiroshima Mineral water making method

Also Published As

Publication number Publication date
JP4644305B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
Hu et al. Ophthalmic manifestations of coronavirus (COVID-19)
Tisdale et al. Neuro-ophthalmic manifestations of coronavirus disease 19
Burns et al. Practical problems with eye-drops among elderly ophthalmology outpatients
JP4644305B1 (en) Eye drops and production method thereof
Abtahi et al. Urbach-wiethe syndrome and the ophthalmologist: review of the literature and introduction of the first instance of bilateral uveitis
Achigbu et al. Visual impairment and blindness in 5 communities in Imo state, South East Nigeria
Anisah et al. Isolation of Acanthamoeba sp. from conjunctival sac of healthy individuals using swab
JP2007077053A (en) Ophthalmic liquid preparation composition
CN107929356A (en) Eyedrops and its preparation method and application
Stewart Amentia, familial cerebellar diplegia, and retinitis pigmentosa
Faktorovich Peer-reviewed literature answers 3 questions about COVID-19 and conjunctivitis
Boal 39-year-old male with new-onset right vision loss
CN107281557A (en) A kind of production technology of contact lenses lubricating fluid
Garza-Leon et al. Medical treatment of crystalline lens dislocation into the anterior chamber in a patient with Marfan syndrome
Gunstensen Visual aids for the partially sighted
Cooper A forecast of the global ocular allergy market
AG et al. A case of non-contact lens related Acanthamoeba keratitis in Malaysia
Chris Diabetes and Aboriginal vision health/Le diabčte et la santé oculaire des Autochtones
Raghunandan et al. Septic cavernous sinus thrombosis–A case report
Panda et al. Study of the Incidence and Various Ocular Manifestations in HIV Positive Cases
Harvey Case study: An option for tired eyes
Patil et al. Epidemiological study of chemical and thermal ocular injuries at a rural hospital in eastern Maharashtra
Geffen Contact Lenses
Rutayisire et al. Ocular manifestations related to HIV/AIDS at Kigali University Teaching Hospital
CN102008419B (en) Skin-cleaning moisturizer

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101203

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees